Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

AzPA Psychiatric Certificate Training Program


AzPA Psychiatric Certificate Program

University of Arizona College of Pharmacy
Drachman Hall-Room B111 
Saturday January 27th, 2018
8:00 AM- 5:00 PM
Program Description: 

The Psychiatric Certificate Program (PCP) is a practice-based activity designed for pharmacists in all practice settings. The intent of this training program is to provide additional training in the area of psychiatric pharmacy to enhance pharmacists’ clinical knowledge that can be applied directly to the patients they serve. 
 

Program Goals:

  • Provide training to enhance a practitioner’s ability to effectively assess, monitor, and manage the pharmacotherapy of patients with psychiatric disorders.
  • Deliver comprehensive medication therapy management to prevent, treat, and control psychiatric disorders using patient-centered care.
  • Promote appropriate and optimal medication use and adherence that minimizes drug interactions, poly pharmacy, and adverse effects.
  • Encourage healthy life styles and non-drug treatment approaches for optimizing a person’s mental and physical health.
 
Psychiatric Certificate Program Learning Objectives: 
  1. Discuss the epidemiology and risk factors for the development of each selected psychiatric disorder.
  2. Describe the typical clinical presentation of each selected psychiatric disorder
  3. Evaluate selected patient cases and determine whether a given patient exhibits signs and/or symptoms of each selected psychiatric disorders.
  4. Describe the clinical course of each selected psychiatric disorder
  5. Compare and contrast the efficacy, safety, tolerability, monitoring parameters, and clinically significant drug interactions of pharmacologic treatment modalities commonly employed in the treatment of each selected psychiatric disorder
  6. Recommend appropriate initial medication therapy and therapeutic alterations/adjustments according to clinical practice guidelines
  7. Recognize and effectively manage common drug interactions associated with the treatment of each selected psychiatric disorders
  8. Formulate appropriate counseling information to be given to patients, or caregivers of patients, prescribed pharmacotherapy for the treatment of each selected psychiatric disorder
  9. Recommend strategies to minimize commonly experienced adverse drug events from prescribed medications.

 

Program Overview:

The Psychiatric Certificate Program is conducted in two parts: the self-study and live training seminar. To earn a certificate of achievement, participants must successfully complete all components of the program, including the self-study modules, the self-study assessment, patient based cases, live training seminar and final examination. All participants are strongly encouraged to attend a Medication Therapy Management training program prior to completing this program but it is not a prerequisite of this course. 

  • Self-Study Description: 
    • Self-Assessment: each participant must complete a self-assessment to gauge their comfort level of the material before completing the program. This will also be assessed again at the conclusion of the live seminar. (PLEASE DO THIS PRIOR TO READING ANY OF THE MATERIAL)
    • Learning Modules: meant to ensure all participants have a basic understanding of psychiatric disorders. Each module has an assigned reading as well as a patient case that must be read and reviewed prior to the live seminar.
      • Module 1: Schizophrenia                                      
      • Module 2: Major Depressive Disorder      
      • Module 3: Bipolar Disorder                                  
      • Module 4: Generalized Anxiety Disorder 
      • Module 5: Sleep Disorders                        
    • Patient Case-Based Exercises (Patient Care Plan): There are patient based exercises at the end of each module that need to be completed as part of the content structure for this activity.  AzPA faculty will verify at the beginning of the live seminar that these plans were completed.
    • Examination for Self-Study: Each participant must complete an online examination and score a 70% or better to receive a passing grade. Your personal testing information will be sent to you separately. Do not start the test unless you plan to finish in one sitting as you will only get 1 attempt.
  • Live Training Seminar:
    • The live training seminar will include didactic presentations as well as interactive training to practice comprehensive medication therapy management skills in the area of psychiatric disorders.
    • You will be required to complete a Final Examination and must receive a score of 70% or above.
    • Upon passing the final examination you will be prompted to complete a final evaluation. This is required in order to complete the Certificate Program and receive your CPEs.

 

Faculty: 

  • Martha Fankhauser, MS Pharm, FASHP, BCPP, Neuropsychiatric Pharmacy
  • Kristyn Straw-Wilson, PharmD, BCPP, Clinical Pharmacy Specialist for Mental Health

 

Fees:

Program Fees
Early Bird Rates
Until 12/30/2017*
Rates
After 12/30/2017*
  • AzPA Member Pharmacist     
$350 $400
  • Non-Member Pharmacist
$450 $500
  • AzPA Member Student
$250 $300
  • Non-Member Student
$300 $350

*Use Coupon Code: PCPJan2018 to get the early bird savings. 

 

Continuing Pharmacy Education (CPE) Credit and Activity Requirements:

Psychiatric Certificate Program has been approved for 25.5 contact hours or (2.55 CEUs). ACPE UAN 0100-0000-15-092-B01-P

  • Initial Release Date: 02-19-2016; Planned Expiration Date: 02/19/2019
  • Activity Type:  Practice-based
  • Learning Level: 2 — Experience with the topic is recommended, but advanced expertise or specialty practice in the subject area is not necessary. This activity will focus on expanding the learner’s knowledge and application of new and/or more complex information.
  • Target Audience:  Pharmacists in all practice settings 
  • Successful completion of the self-study component involves passing the self-study exam with a grade of 70% or higher and will result in 17.5 contact hours of CPE credits (1.75 CEUs). 
  • Successful completion of the live seminar component involves attending the full live seminar, passing the final exam with a grade of 70% or higher and completing a final evaluation. Successful completion of this component will result in 8.0 contact hours of CPE credit (0.80 CEU). 

 

Activity Completion Requirements: A Certificate of Achievement is awarded to participants who successfully complete all activity requirements, which include the self assessments, the self-study activity, the self-study exam, the live training seminar, and the final exam and evaluation. The self-study materials must be completed prior to the live session. We will upload all credits 30 days from the live session date. It is the participants responsibility to ensure your credits are uploaded within 60 days from the live session date. After this time you will no longer be able to claim your CPE credit.

 

Refund Policy: Refund and/or cancellation requests must be made in writing to the Arizona Pharmacy Association office. A cancellation request made at least two weeks prior to the scheduled program will require $100.00 fee (cancellation fee plus the cost of printed materials). A cancellation request made 10 business days or less prior to the schedule program will require a $150 fee (cancellation plus printed materials, plus cost of food order). You must submit a written request to cancel by email, fax or standard mail. No refunds will be issued for cancellation requests received after the posted start date / time of the scheduled program. AzPA reserves the right to cancel any activity due to insufficient pre-registration and as determined by the Executive Director or CE Administrator. In this case, all individuals pre-registered are notified and issued a full refund. Registration fees cannot be re-allocated to future offerings of this certification program due to the multiple steps involved with processing CE credits. 

 

Date: Jan 27, 2018 08:00 AM - 05:00 PM

CE Hours

25.50

CE Units

2.550

Registration closes on Jan 25, 2018 05:00 PM

Target Audience(s)

  • Pharmacists
  • Student

Accreditation(s)

Accreditation Council for Pharmacy Education
The Arizona Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as providers of continuing education.

 

 

 

   

Module 1:  Schizophrenia
 
At the completion of this home-study module, the participant should be able to:
  1. Discuss the epidemiology and risk factors for the development of schizophrenia.
  2. Evaluate if a patient meets the DSM-IV-TR criteria for schizophrenia, including different subtypes. 
  3. Distinguish between common symptoms of schizophrenia including positive, negative, and cognitive symptoms.
  4. Apply treatment algorithms and clinical practice guidelines to specific patients to recommend initial and subsequent therapy (e.g., The Texas Medication Algorithm Project).
  5. Compare and contrast side effects and efficacy of different pharmacological treatments used in schizophrenia.
  6. Given a patient with schizophrenia, develop an effective monitoring plan.
  7. Recommend how to treat an acutely agitated, aggressive, or hostile patient with schizophrenia.
  8. Recognize and effectively manage common drug interactions with antipsychotics.
  9. Describe the most common co-existing symptoms of schizophrenia and be prepared to recommend an effective treatment. 
  10. Recognize the most common movement disorders caused by antipsychotic medications.
  11. Discuss the different pharmacological and nonpharmacological treatment options available for movement disorders.
     
 
 
 
 
 

   

   

Module 2:  Major Depressive Disorder
 
At the completion of this home-study module, the participant should be able to:
  1. Discuss the epidemiology and risk factors for the development of major depressive disorder (MDD).
  2. List the major symptoms exhibited in a patient suffering from MDD as defined by the DSM-IV-TR.
  3. Identify reversible risk factors and medications that can contribute to MDD.
  4. Discuss the importance of assessing suicide risk in patients with MDD and be able to counsel patients on suicide as it related to MDD.
  5. Describe the different phases of treatment with MDD and the goal of each phase of treatment.
  6. Determine first line and subsequent therapy for an individual with MDD based on the Texas Medication Algorithm Project.
  7. Compare and contrast the side effect profile of individual antidepressants.
  8. Formulate a monitoring plan for a patient on a given antidepressant based on the individual and the pharmacotherapy that is chosen. 
  9. Formulate appropriate counseling information to be provided to a patient on antidepressant therapy. 
  10. Identify treatment options for patients who develop treatment-resistant MDD.
     
 

   

   

Module 3:  Bipolar Disorder
 
At the completion of this home-study module, the participant should be able to:
 
  1. Define bipolar disorder and recognize the symptoms associated with this disorder.
  2. Understand DSM-IV-TR criteria and classification of bipolar disorder. 
  3. Discuss the pathophysiologic mechanisms of bipolar disorder.
  4. Describe the efficacy of medications utilized to treat bipolar disorder.
  5. Explain the mechanism of action of medications utilized to treat bipolar disorder.
  6. Differentiate between the various medications for bipolar disorder with respect to therapeutic use and adverse effects.
  7. Describe the factors that should be considered when designing a drug therapy treatment regimen for an individual with bipolar disorder.
  8. Recognize important drug-drug interactions associated with current medications utilized to treat bipolar disorder.
  9. Develop a plan for laboratory and clinical monitoring parameters to ensure the safety of medications utilized to treat bipolar disorder.
  10. Recommend appropriate counseling information that should be given to patients prescribed medications to treat bipolar disorder, including nonpharmacologic treatments.
 
     

   

   

Module 4:  Anxiety Disorders
 
At the conclusion of this home-study module, the participant should be able to:
 
  1. Using the DSM-IV-TR criteria, evaluate selected patient cases and determine whether a given patient exhibits signs and/or symptoms of: Generalized Anxiety Disorder (GAD),
  2. Panic Disorder (PD), and Social Anxiety Disorder (SAD) – also called “Social Phobia”.
  3. Describe the yypical clinical presentation of GAD, PD, and SAD.
  4. Describe the expected clinical course of GAD, PD, and SAD.
  5. Describe nonpharmacological treatment strategies with anticipated effectiveness for each strategy used in the treatment of GAD, PD and SAD.
  6. Discuss the use and role of pharmacotherapy for the treatment of GAD, PD, and SAD.
  7. Prepare and defend a clinical paradigm (decision tree, algorithm) for the pharmacotherapeutic treatment of GAD, PD, and SAD.
  8. Distinguish differences in pharmacology, kinetics, efficacy, dosing, adverse effects and drug interactions for the various medications used in the treatment of anxiety disorders.

   

   

Module 5:  Sleep Disorders
 
At the completion of this home-study module, the participant should be able to:
  1. Describe the clinical presentation and diagnostic criteria for insomnia, periodic limb movements during sleep (PLMS), restless legs syndrome (RLS), obstructive sleep apnea, and narcolepsy.
  2. Explain mechanism of action and dosing considerations for pharmacologic therapies used in the management of sleep disorders including appropriate initiation and titration of therapy.
  3. Develop a therapeutic plan for sleep disorders including pharmacologic and nonpharmacologic treatments based on a patient’s presentation.
  4. Recommend appropriate counseling information and patient education (including sleep hygiene) for patients or caregivers of patients with a sleep disorder. 
  5. Identify special patient population concerns about sleep disorders.
 

   

   

Module 6:  Attention-Dificit Hyperactivity Disorder
 
At the completion of this home-study module, the participant should be able to:
 
  1. Identify and describe target symptoms and behaviors of Attention-Deficit/Hyperactivity Disorder (ADHD).
  2. State the three sub-types of ADHD according to the DSM-IV-TR and the diagnostic criteria for ADHD.  
  3. Discuss potential genetic and non-genetic factors associated with the development of ADHD.
  4. Describe the clinical course of ADHD including through adulthood.
  5. Explain the idea of multimodal treatment approach for ADHD.
  6. Compare and contrast the efficacy, safety, tolerability, monitoring parameters, and clinically significant drug interactions of pharmacologic treatment modalities commonly used in the treatment of ADHD. 
  7. Compare the advantages and disadvantages of stimulant and non-stimulant medications with regard to effectiveness and abuse potential.
  8. Recommend appropriate initial medication therapy and therapeutic alterations/adjustments according to clinical practice guidelines for a patient with ADHD. 
  9. Recommend appropriate counseling information to be given to patients, or caregivers of patients, prescribed pharmacotherapy for the treatment of ADHD. 
  10. Recommend strategies to minimize commonly experienced adverse drug events from ADHD medications.
  11. Discuss clinical controversies in the treatment of ADHD. 

   

   

AzPA Psychiatric Certificate Program

University of Arizona College of Pharmacy
Drachman Hall-Room B111 
Saturday January 27th, 2018
8:00 AM- 5:00 PM

Agenda:

7:00AM-8:00AM: Registration

  • No breakfast will be provided-plan accordingly by bringing your own snacks/coffee

8:00AM-12:15PM: AM Sessions

  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorders
  • Q&A 

12:15PM-1:00PM: Lunch Break

  • We will be ordering pizza for lunch- please bring your own drinks 

1:00PM-5:00PM: PM Sessions

  • Anxiety Disorders
  • Case I:  Depression and Anxiety
  • Sleep Disorders
  • Case II: Schizophrenia and Insomnia
  • Attention Deficit/Hyperactivity Disorder
  • Case III: Bipolar Disorder and ADHD
  • Q&A

 

Pharmacotherapy Care Plans:

  • Please bring these with you to the live seminar. 

 

Live Training Seminar:

  • The live training seminar will include didactic presentations as well as interactive training to practice comprehensive medication therapy management skills in the area of psychiatric disorders.
  • You will be required to complete a Final Examination and must receive a score of 70% or above. The exam will be taken online within the same online program you completed the home study materials. 
  • Upon passing the final examination you will be prompted to complete a final evaluation. This is required in order to complete the Certificate Program and receive your certificate and CPE's.
 

 

Activity Number

0100-0000-15-092-B01-P
Date: 01/27/18
Time: 08:00 AM - 05:00 PM

CE Hours

25.50